Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19)
Thrombotic Thrombocytopenia Syndrome (TTS) has emerged as a new adverse event following immunization in individuals vaccinated with COVID-19 non-replicant adenovirus vector-based vaccines (AstraZeneca COVID-19 ChAdOx-1 vaccine and Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccine)...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Geneva
World Health Organization
[2023], 2023
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Thrombotic Thrombocytopenia Syndrome (TTS) has emerged as a new adverse event following immunization in individuals vaccinated with COVID-19 non-replicant adenovirus vector-based vaccines (AstraZeneca COVID-19 ChAdOx-1 vaccine and Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccine). TTS is a serious and life-threatening adverse event. WHO has issued this interim emergency guidance to increase awareness about TTS in the context of COVID-19 vaccination and help healthcare providers in the assessment and management of potential TTS cases. Knowledge about TTS following vaccination with a COVID-19 adenovirus vector-based vaccine is rapidly evolving. WHO will continue to monitor the situation closely for any changes that may affect this interim guidance and will update the guidance as needed |
|---|---|
| Physical Description: | 1 PDF file (41 pages) illustrations |
| ISBN: | 9789240061996 9789240061989 |